Resistance to thyroid hormone (RTH) has hitherto been associated with thyroid hormone β receptor (TRβ) mutations which cluster in two regions (αα 310-353 and αα 429-461) of the hormone-binding domain and closely approximate the ligand-binding cavity. Here, we describe a third cluster of RTH mutations extending from αα 234-282 which constitute a third boundary of the ligand pocket. One mutant, T277A, exhibits impaired transactivation which is disproportionate to its mildly reduced ligand affinity (K a ). T3-dependent recruitment of coactivators (SRC-1, ACTR) by mutant receptor-RXR heterodimers was reduced in comparison with wild-type. Cotransfection of SRC-1 restored transactivation by T277A. In the TRβ crystal structure this helix 3 residue is surface-exposed and is in close proximity to residues L454 and E457 in helix 12 which are known to be critical for coactivator interaction, suggesting that they all constitute part of a receptorcoactivator interface. The transcriptional function of other mutants (A234T, R243W/Q, A268D, Δ276I, A279V, R282S) in this cluster correlated with their reduced K a and they inhibited wild-type TRβ action in a dominant negative manner. DNA binding, heterodimerization and corepressor recruitment were preserved in all mutants, signifying the importance of these attributes for dominant negative activity and correlating with the absence of natural mutations in regions bordering the third cluster which mediate these functions.
Introduction
In keeping with other members of the nuclear receptor family, TRβ is a ligand-inducible transcription factor with a modular structure comprised of a central DNA-binding (C) domain flanked by a C-terminal (D/E/F) region that encompasses ligand binding, dimerization and hormonedependent transactivation functions and an N-terminal (A/B) region implicated in ligand-independent transactivation (Mangelsdorf and Evans, 1995) . In many target genes, TR interacts with regulatory DNA response elements typically consisting of hexanucleotide motifs oriented as direct, inverted or everted repeats. TR functions primarily as a heterodimer with the retinoid X receptor (RXR) but can function as a homodimer in some contexts (Lazar, 1993) . In the absence of ligand, TR actively represses basal gene transcription by recruiting a complex containing corepressor proteins (SMRT or NCoR) (Chen et al., 1995; Hörlein et al., 1995) associated with a histone deacetylase (HDAC) via an intermediary factor (Sin3) (Heinzel et al., 1997; Nagy et al., 1997) . Receptor occupancy by T3 results in dissociation of this corepressor complex and derepression, followed by recruitment of coactivators and associated cofactors (e.g. RIP140, SRC-1, TIF-2, CBP, ACTR, p/CAF) exhibiting histone acetyltransferase activity, as well as other associated factors, subsequently leading to transcriptional activation (Cavailles et al., 1995; Chen et al., 1997; Oñate et al., 1995; Chakravarti et al., 1996; Kamei et al., 1996; Voegel et al., 1996) . Residues at the extreme C-terminus in many nuclear receptors have been shown to be critical for coactivator recruitment, and recent crystallographic studies indicate that these residues lie within a solvent-exposed amphipathic α-helix which may undergo a conformational change in response to ligand (Renaud et al., 1995) . However, the role of other regions of the receptor which might play a part in this recruitment remains to be determined.
Over 70 different natural TRβ mutations have been identified in the syndrome of resistance to thyroid hormone (RTH), the hallmark feature of which is elevated circulating free thyroid hormones (thyroxine, T4 and triiodothyronine T3) together with non-suppressed levels of thyroid stimulating hormone (TSH). These mutations all occur within the C-terminal ligand-binding domain (LBD) and characterization of their properties has made a valuable contribution to the understanding of structure-function relationships in TR. With a few exceptions, a consistent abnormality with natural receptor mutants is a significant reduction in their ligand-binding affinity resulting in impaired hormone-dependent transcriptional activity (Meier et al., 1992; Collingwood et al., 1994) . In addition, the mutant receptors inhibit the action of their wild-type counterparts in a dominant negative manner (Sakurai et al., 1990; Chatterjee et al., 1991) , a property which is central to the pathogenesis of the RTH phenotype and consistent with their dominant mode of inheritance. This inhibitory effect is dependent on their ability to bind to DNA (Nagaya et al., 1992) , heterodimerize with RXR (Nagaya and Jameson, 1993; Collingwood et al., 1994) and recruit corepressor (Yoh et al., 1997) . These findings correlate with the observation that no natural RTH mutations have been identified in the DNA-binding domain (DBD) of TRβ and, moreover, that the majority of mutations occur in two clusters (αα 310-353; αα 429-461) wherein the intervening region contains a putative dimerization interface implicated in receptor interaction with RXR (Forman and Samuels, 1990 ). We have also described RTH mutants that interact aberrantly with transcriptional cofactors: a natural mutant, L454V, with relatively preserved ligand-and DNA-binding and dimerization functions (Collingwood et al., 1997) was impaired transcriptionally as a result of attenuated interaction with putative coactivators (RIP140, SRC-1); another mutant, R383H, was predominantly impaired for negative transcriptional regulation and hormone-dependent corepressor release (Clifton-Bligh et al., 1998) .
Here, we report a mutant (T277A) within a third natural mutation cluster (αα 234-282), which is impaired transcriptionally with reduced coactivator binding. We suggest that helix 3 of the LBD which encompasses this residue, together with helix 12, may constitute part of a wider receptor-coactivator interface. Other natural mutants in this cluster show variably impaired ligand binding and transcriptional function and inhibit wild-type TR action in a dominant negative manner, but retain DNA-and corepressor-binding and heterodimerization functions. These observations may explain the absence of naturally occurring mutations in receptor domains (α-helical extension of the DBD, signature motif, CoR box) bordering this third cluster.
Results

Genotype and clinical phenotype of RTH cases
Thyroid function tests and receptor gene abnormalities in affected members of 14 different RTH families are shown in Table I . Most individuals exhibited biochemical abnormalities characteristic of RTH with elevated serum-free T4 and T3 levels together with an inappropriately normal TSH. Three patients (IV, IX, XIII.I) had undergone a previous subtotal thyroidectomy, disrupting the pituitarythyroid feedback axis, resulting in variably elevated TSH levels with raised (IV, IX) or normal (XIII.I) serum-free T4 concentrations. Sequencing of the TRβ gene indicated that each affected individual was heterozygous for either a single nucleotide substitution corresponding to a missense mutation or, in one case, a three nucleotide in-frame codon deletion (Δ276I). Five novel mutations (A268D, Δ276I, T277A, A279V, R282S) have not been described previously in RTH. In addition, we have identified and characterized more extensively mutations (V264D, A234T, R243W, R243Q) which have been documented as case reports (Behr and Loos, 1992; Adams et al., 1994; Onigata et al., 1995; Pohlenz et al., 1996) . In one instance (II), a de novo R243W mutation exists in the proband but not in either parent, supporting the hypothesis that these identical mutations have arisen independently in unrelated families.
RTH mutant receptors show variably impaired transactivation function
In keeping with their location in the TR LBD, the initial characterization of mutant receptors consisted of measurement of the ligand-binding affinities (K a ) of in vitro synthesized proteins. All showed variably reduced T3 binding, with a few (A279V, A268D, Δ276I) having affinities too low to quantitate (Table I) . To evaluate their transcriptional properties, wild-type or mutant receptors were cotransfected with reporter genes containing one of three different types of thyroid response element (TRE) into JEG-3 cells with increasing concentrations of T3. All mutants were impaired transcriptionally on the direct repeat (MAL-tkLUC), everted repeat (F2-tkLUC) and palindromic (PAL-tkLUC) TREs ( Figure 1A -C) and, as expected, those mutants with greatly reduced ligand binding (A279V, A268D, Δ276I) showed the greatest transcriptional impairment, demonstrating submaximal responses even in the presence of saturating concentrations (1000 nM) of T3. For most mutants with measurable ligand-binding affinities (A234T, R243Q, R243W, R282S), the extent of their transcriptional impairment when compared with wild-type receptor correlated negatively with their K a ( Figure 1D-F) . However, a single mutant, T277A, exhibited submaximal transactivation on MAL-tkLUC and F2-tkLUC, despite saturating T3 concentrations ( Figure  1A and B), but not on PAL-tkLUC ( Figure 1C ). Furthermore, the T3 concentration required for T277A to attain 50% wild-type receptor activity on the direct repeat and everted response elements was markedly discordant with its K a ( Figure 1D and E). This pattern of transcriptional impairment suggested that the T277A mutation might disrupt some function of the receptor other than ligand binding.
Reduced transactivation by the T277A mutant is due to impaired coactivator recruitment The attenuated maximal transactivation attained by the T277A mutant on MAL-tkLUC and F2-tkLUC was analogous to the activation profiles on these reporters of a number of mutants of a proline residue (P453A/H/S/T) which precedes the C-terminal amphipathic α-helix of TR . Subsequent studies have shown that the P453S mutant receptor impairs hormone-dependent corepressor release to a greater extent than predicted from its reduced ligand-binding affinity (Yoh et al., 1997) . Hence, we examined whether the impaired transcriptional function of T277A might also be accounted for by abnormal corepressor release. Wild-type TR dissociated from GST-SMRT in response to T3 with an EC 50 of 4 nM (Figure 2 ). In contrast, the T277A mutant showed impaired ligand-dependent corepressor release such that its EC 50 was 20 nM (Figure 2) . However, the R282S mutant receptor, which has an almost identical K a in comparison with T277A (Table I ), yet transactivates fully ( Figure 1A -C), showed a similar alteration in corepressor release (Figure 2) . We conclude that the delayed corepressor release profiles exhibited by these two mutant receptors are in keeping with their reduced K a and do not account for the diminished transcriptional function shown by T277A.
We have shown previously that another RTH mutant with markedly impaired transactivation, L454V, exhibited reduced coactivator recruitment in vitro (Collingwood et al., 1997) . Accordingly, we next examined the ability of wild-type or T277A mutant receptors to recruit coactivator proteins when bound to DNA as a heterodimer with RXR. Wild-type TR-RXR complexes, when bound to the direct repeat TRE, recruited glutathione S-transferase (GST) fusion proteins containing the central receptor-interacting domains of either SRC-1 (GST-SRCЈ; residues 570-780) or ACTR (GST-ACTRЈ; residues 621-821) in a T3-dependent manner ( Figure 3A and B). In contrast, recruitment of GST-SRCЈ by T277A-RXR heterodimers on this response element was diminished ( Figure 3A) , with maximal coactivator recruitment reduced to 60% that of wild-type TR when quantitated (data not shown). Hormone-dependent recruitment of GST-ACTRЈ by T277A was also markedly impaired in comparison with wild-type ( Figure 3B ). These results suggest that reduced coactivator recruitment by T277A in vitro might account for its impaired transactivation in vivo. Indeed, we hypothesized that if impaired recruitment of endogenous coactivators was limiting the maximal transcriptional response of the T277A mutant, then overexpression of such factors might alleviate this defect. Accordingly, wild-type or T277A mutant receptors were cotransfected with Mal-tkLUC and increasing amounts (0-100 ng) of SRC-1 expression vector (Figure 4 ). Whereas the basal promoter (RSV) activity in mock-transfected cells or hormone-dependent activation by wild-type receptor were not affected significantly by co-expression of SRC-1, the transcriptional response of the T277A mutant was enhanced to wild-type levels.
Dominant negative activity of mutant receptors in the third cluster
It has been suggested that mutant receptors inhibit the action of wild-type receptor in a dominant negative manner to manifest the RTH phenotype ; JEG-3 cells were cortransfected with 50 ng of RSV-TR wild-type or T277A mutant or empty vector, along with increasing amounts of pSG5-SRC1, as well as 500 ng of reporter MAL-TKLUC and 100 ng of the internal control Bosβgal. Empty pSG5 vector was added to maintain the amount of total DNA transfected. Cells were incubated in the presence or absence of 1 μM T3. Data are the mean Ϯ SE of three separate experiments performed in triplicate and activity is expressed relative to wild-type T3-dependent activation at 100 ng SRC-1. 5 . Dominant negative inhibition of wild-type receptor activity by mutant receptors on different TRE configurations. JEG-3 cells were cotransfected with equal amounts (100 ng) of wild-type plus each mutant TRβ expression plasmid, along with the specified reporter constructs (A) PAL-tkLUC, (B) F2-tkLUC or (C) MAL-tkLUC and an internal control plasmid (BOS-βgal). The transfected cells were incubated in the presence of either low (1 nM; solid bars) or high (1000 nM; white bars) concentrations of T3. Hormone-dependent activation was normalized against the internal control and expressed as the percentage of maximum wild-type receptor response at each concentration of T3. These data are the mean Ϯ SE of at least three separate experiments performed in triplicate. Yen and Chin, 1994) . We therefore examined the dominant negative potency of RTH mutants by co-expressing equal amounts of each with wild-type TR, again using three reporter genes containing different configurations of TRE in the presence of low (1 nM) or high (1000 nM) levels of T3 ( Figure 5A -C). At 1 nM T3 all mutants showed marked dominant negative inhibition of wild-type receptor function on all three TREs. Reversal of this inhibition for some mutants (R243Q, R243W, R282S) at higher (1000 nM) T3 concentrations was in keeping with their ability to attain wild-type transactivation levels with saturating levels of ligand. Other mutants (A268D, Δ276I, A279V, T277A, A234T) retained dominant negative activity at high T3 levels, presumably as a consequence of marked impairment either in hormone binding and/or transactivation function.
DNA binding and heterodimerization with RXR is preserved for all RTH mutants
One proposed mechanism of dominant negative inhibition by mutant receptors suggests that they form transcriptionally defective heterodimers with RXR which bind to DNA and compete with wild-type TR-RXR complexes at target gene TREs (Yen and Chin, 1994) . Accordingly, we used an electrophoretic mobility shift assay to examine these properties for each RTH mutant using the three different TRE configurations utilized previously to test their transcriptional function ( Figure 6A-C) . All the RTH mutants bound DNA and heterodimerized with RXR comparably with wild-type receptor on palindromic (PAL), everted repeat (F2) or direct repeat (malic enzyme) TREs. In addition, both wild-type and mutant receptors bound DNA as homodimers with the everted repeat TRE ( Figure 6B ). In response to ligand (10 nM T3) the wildtype TR homodimer dissociated from DNA as described previously , whereas the variable dissociation of the RTH mutant homodimers was concordant with their reduced ligand binding.
Mutant receptors recruit corepressor and repress basal transcription
Recent studies have suggested that the ability to silence basal transcription and recruit corepressor are important attributes of RTH mutants and that the introduction of additional artificial mutations which abolish corepressor binding abrogates their dominant negative activity (Yoh et al., 1997) . We therefore examined the ability of each mutant to repress basal transcription by co-expressing fusions of wild-type or mutant TR LBDs linked to the DNA-binding domain (DBD) of Gal4 with a reporter gene containing Gal4-binding sites. In the absence of ligand, the wild-type Gal4-TR fusion repressed basal transcription to~15% of that observed with the Gal4 DBD alone. In comparison, each RTH mutant repressed to a similar degree, suggesting that corepressor recruitment was preserved ( Figure 7A ). In contrast, two artificial mutants (P214R, L428R) exhibited markedly impaired silencing function. The P214R substitution is homologous to a natural mutation which reverses oncogenesis and dominant negative activity of v-erbA (Damm and Evans, 1993) . We and others have previously shown that the L428R mutation abolishes both receptor dominant negative activity and heterodimerization with RXR (Nagaya and Jameson, 1993; Collingwood et al., 1994) , and recently the homologous TRα mutant (L374R) has been shown to lack corepressor interaction (Zhang et al., 1997) .
From these observations, we hypothesized that the interaction of each mutant receptor with corepressor is retained, and we tested this by studying the interaction between bacterially expressed GST-SMRT fusion protein and 35 S-labelled, in vitro translated mutant receptors. In the absence of ligand, all RTH mutants bound SMRT comparably with wild-type receptor ( Figure 7B ). Following the addition of saturating concentrations (1 μM) of T3, most mutants dissociated from corepressor although, as expected, those with markedly reduced ligand-binding affinity (V264D, Δ276I, A268D) exhibited impaired hormone-dependent corepressor release.
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Discussion
A third cluster of mutations in resistance to thyroid hormone
The association of dominantly inherited RTH with the TRβ gene locus has led to the identification of an expanding repertoire of mutations in the receptor-hormone binding domain. Rather than being uniformly distributed, they cluster mainly in two areas (αα 310-353; αα 429-461) within the LBD (Parrilla et al., 1991; Refetoff et al., 1993) . There have been isolated reports of amino acid changes involving three codons outside these two clusters: our previous description of a valine to aspartic acid substitution at codon 454 (V264D; Adams et al., 1994; Collingwood et al., 1994) ; an alanine to threonine substitution at codon 234 (A234T; Behr and Loos, 1992) ; and two different substitutions at codon 243 (R243W, R243Q: Onigata et al., 1995; Pohlenz et al., 1996) . Here, we report five novel TRβ mutations (A268D, Δ276I, T277A, A279V, R282S), together with the identification of known mutations (A243T, R243W, R243Q), in further families with RTH which constitute a third cluster of abnormalities localizing to a distinct part (αα 234-282) of the (E) domain of the receptor. We have characterized these mutants extensively to determine their functional properties. When tested with reporter genes containing three different configurations of TRE, the extent to which their transcriptional function was impaired (Figure 1 ) was correlated inversely with ligand-binding affinities with the notable exception of T277A.
Identification of a role for helix 3 in liganddependent transactivation and the recruitment of coactivators
One mutant, T277A, within the third cluster showed substantially reduced transactivation compared with the wild-type maximum, despite levels of T3 sufficient to overcome its reduced ligand-binding affinity. Recently, mutants involving another codon in this region (R243W/ Q) were found to exhibit a similar transcriptional phenotype (Yagi et al., 1997) which was explicable on the basis of markedly lower ligand-binding affinities of DNAbound versus free mutant proteins. However, the ready dissociation of T277A mutant homodimers ( Figure 6B ) and conformational change of T277A heterodimers ( Figure 6A ) in the presence of ligand makes a similar explanation unlikely, implying that other properties integral to receptor function might be impaired. We considered the possibility that T3-dependent dissociation of corepressor from this mutant might be disproportionately impaired, as described with mutants involving proline 453, which precedes the C-terminal amphipathic α-helix (Yoh et al., 1997) , and an unusual mutant, R383H, located outside the three clusters (Clifton-Bligh et al., 1998) . However, impaired corepressor release by T277A was consistent with its reduced K a (Figure 2) . In contrast, hormone-dependent recruitment of coactivators (SRC-1, ACTR) by T277A-RXR heterodimers on a direct repeat TRE was significantly attenuated ( Figure 3A and B), which correlated with marked transcriptional impairment on this element. Furthermore, overexpressing SRC-1 restored the transcriptional function of this mutant (Figure 4 ), supporting our contention that defective coactivator recruitment limits its activity in vivo.
A number of studies have shown that the C-terminal amphipathic α-helix is important for ligand-dependent transactivation (AF-2) and coactivator recruitment both in TR and other nuclear receptors (Danielian et al., 1992; Barettino et al., 1994; Durand et al., 1994; Tone et al., 1994) . We have reported a natural RTH mutant involving a leucine to valine substitution at codon 454 (L454V) in helix 12 of TRβ LBD which exhibits similarly attenuated transactivation due to reduced ability to recruit putative coactivators, such as SRC-1 and RIP140, and that artificial mutations of this hydrophobic (L454A) and a neighbouring charged residue (E457A) abrogate both of these functions Collingwood et al., 1997) . The present study reveals that an additional residue, a threonine located at codon 277 in helix 3 (T277), is also critical for AF-2 activity and coactivator recruitment. Furthermore, an artificial TRβ mutant (K288I) situated at the distal end of helix 3 has previously been observed to impair transactivation while preserving ligand binding (O'Donnell and Koenig, 1990) . More recently, mutation of the homologous residue (K366A) in the oestrogen receptor has been shown to reduce SRC-1 binding dramatically (Henttu et al., 1997) .
In the crystal structure of hTRβ those residues in helix 12 (L454, E457) and helix 3 (T277, K288) that are critical for transactivation are in close physical proximity (Figure 8) . Furthermore, the side chains of each of these residues are solvent exposed and, as such, are potentially capable of mediating interactions with cofactors. We suggest that these residues might collectively constitute a coactivator-interaction surface. A parallel crystallographic study supports this hypothesis, showing that a peptide containing an LXXLL motif, characteristic of the receptorinteracting domains of many coactivators (Heery et al., 1997) , binds the TR in a hydrophobic cleft bordered Preserved DNA-binding, heterodimerization, silencing and corepressor interaction are characteristic of mutations in the third cluster The observation that individuals heterozygous for a deletion of a single TRβ allele did not exhibit RTH (Takeda et al., 1992) led to the hypothesis that mutant receptors in this syndrome were not simply functionally impaired, but were also capable of inhibiting wild-type receptor function in a dominant negative manner. A number of studies have shown that dominant negative activity is an intrinsic property of RTH mutants within the two previously recognized clusters (Sakurai et al., 1990; Chatterjee et al., 1991; Meier et al., 1993; Zavacki et al., 1993; Collingwood et al., 1994; Hayashi et al., 1994; Kitajima et al., 1995) . We have tested mutants located in the third cluster and find that they also exert dominant negative inhibitory effects when cotransfected with wild-type TR on three different TREs ( Figure 5A-C) . Previous studies have shown that three properties are essential for dominant negative activity of mutant receptors, DNA binding, dimerization with RXR and corepressor recruitment, such that the introduction of artificial mutations which abolish these functions abrogates dominant negative inhibition (Nagaya et al., 1992; Nagaya and Jameson, 1993; Collingwood et al., 1994; Yoh et al., 1997) . Although the hinge and D domain of TR have been implicated previously in DNA binding, heterodimerization and corepressor interaction, we found that without exception all mutants within the third cluster retained the ability to bind to DNA and heterodimerize with RXR on palindromic, direct or everted repeat TREs (Figure 6A-C) . Moreover, they silence basal transcription in vivo ( Figure 7A ) and recruit corepressor (Rastinejad et al., 1995) , the CoR box implicated in recruitment of corepressor (Hörlein et al., 1995) and a signature motif conserved amongst nuclear receptors and involved in stabilizing the canonical fold of the LBD (Wurtz et al., 1996) . The third cluster of RTH mutations extends from αα 234-282. Non-RTH mutants which interfere with either corepressor (P214R, AHTm) or coactivator interaction (K288I, K306A) are italicized and the beginning of the next RTH mutation cluster at M310 is boxed. (B) Mapping of the third cluster of RTH mutations onto the TRβ crystal structure. Ribbon drawing of the ligand binding domain with α-helices and coil conformations shown in grey. The hormone (magenta) is depicted as a space-filling model. The boundaries of the three clusters within which RTH mutations localize are coloured: brown (residues 310-353), blue (residues 429-461) and green (residues 234-282). The side chains of mutated codons within the third cluster are shown, forming another boundary to the ligand binding cavity. Receptor regions that are devoid of naturally occurring mutations are marked: the signature motif (boxed) involved in folding of the LBD and part of helix 11 (arrowed) mediating dimerization. The CoR box involved in corepressor binding is bracketed and the direction of the α-helical extension of the DBD is arrowed.
comparably with wild-type TR in vitro ( Figure 7B) . Analysis of the boundaries of the third cluster suggest that there are important functional constraints which explain the lack of naturally occurring mutations beyond it ( Figure 9A ). The crystal structure of the DNA-bound TR-RXR heterodimer has shown that the region proximal to the third cluster forms an α-helix interacting with the minor groove (Rastinejad et al., 1995) and furthermore, domain-swap experiments have suggested that this region enables monomeric DNA binding by TR (Zechel et al., 1994) . This C-terminal extension to the DNA-binding domain is followed by a region (residues 211-238; the CoR box) implicated in corepressor recruitment (Hörlein et al., 1995) . Indeed, a point mutant within this sequence (P214R) is impaired for silencing ( Figure 7 ) and binding to SMRT (Chen and Evans, 1995) and abolishes the dominant negative activity of v-erbA, the oncogenic counterpart of TR (Damm and Evans, 1993) . In addition, a triple point mutation (A228M/H229M/T232M) in this region disrupts binding to NCoR (Hörlein et al., 1995) and reverses dominant negative inhibition by RTH mutants (Yoh et al., 1997) . One RTH mutant (A234T) lies within the CoR box but recruits corepressor normally, suggesting that not all residues in this region are critical for corepressor binding. C-terminal to the third cluster is a sequence (αα 286-305) which is so highly conserved among nuclear receptors that it has been termed the 'signature motif'. Recent studies have shown that this region is critical for dimerization with RXR, not only for TR, but also for RAR and VDR (O'Donnell et al., 1991; Rosen et al., 1993; Whitfield et al., 1995) . Elucidation of the crystal structures of several nuclear receptor LBDs (Bourguet et al., 1995; Renaud et al., 1995; Wagner et al., 1995) indicate that residues in this motif mediate interhelical interactions which stabilize the hydrophobic core. We speculate that mutations occurring in this region would not cause RTH because they would disrupt folding of the LBD-and RXR-binding and therefore not function as dominant negative inhibitors of wild-type TR.
A third boundary to the ligand-binding cavity in the crystal structure of TRβ is provided by residues in the new cluster Two clusters of mutations occurring in RTH (αα 310-353; αα 429-461) have been shown previously to border the ligand-binding cavity when mapped to their homologous residues in the crystal structure of TRα (Wagner et al., 1995) . When the mutations occurring in our third cluster are mapped onto the TRβ crystal structure ( Figure 9B ) these residues are seen to form a further boundary to the ligand-binding pocket. Indeed, some mutations (Δ276I, A279V) involve residues whose side chains contact ligand directly, an observation concordant with these mutations being particularly deleterious for hormone binding. Collectively, our studies of a third cluster of naturally occurring mutations in RTH have delineated new struc-ture-function relationships for TRβ and emphasize the value of studying RTH as a model for understanding transcriptional regulation by this nuclear receptor. and free T3 (FT3) levels (shown in Table I) were measured with fluoroimmunometric (FIA) assays using Delfia technology (Wallac, Milton Keynes, UK). TSH levels were determined with a sensitive 'second generation' assay method (Delfia, Wallac, Milton Keynes, UK). The intra-and interassay coefficients of variation were Ͻ10% throughout.
Materials and methods
Clinical and genetic analyses
Blood samples were obtained from members of each kindred and leucocyte DNA was extracted using standard techniques. For each index case, exons 4-10 of the hTRβ gene were amplified by PCR from genomic DNA with flanking intronic oligonucleotide primers and sequenced directly as described previously (Collingwood et al., 1997) . Each mutation was verified with at least two independent PCRs and sequencing reactions and family members were also genotyped by direct sequencing.
Expression vectors and reporter constructs
Receptor mutations were generated by site-directed mutagenesis of human TRβ1 cDNA and verified by sequencing as described previously (Collingwood et al., 1997) . A eukaryotic vector containing the Rous sarcoma virus (RSV) enhancer and promoter was used to express wildtype and mutant human TRβ cDNAs (Collingwood et al., 1997) . The reporter plasmids MAL-tk, PALtk and F2-tk contain direct, palindromic or everted repeat configurations of TRE upstream of the viral thymidine kinase (tk) promoter and luciferase (LUC) gene as described .
The Gal4-TR expression vectors consist of the hormone-binding domains of wild-type or mutant TRβ (residues 174-461) coupled to the DNA-binding domain (residues 1-147) of Gal4. The reporter UAS-TKLUC contains two 17mer Gal4 binding sites upstream of the TK promoter and luciferase . The internal control plasmid BOS-βgal contains the elongation factor-1α promoter driving expression of the lacZ gene. The expression vector pSG5-SRC-1 contains a human SRC-1 cDNA isolated from a B-cell library (Collingwood et al., 1997) .
T3-binding assays
Mutant receptor cDNAs were subcloned into pGEM 7z and used as templates for coupled in vitro transcription and translation with rabbit reticulocyte lysate (TNT, Promega, Southampton, UK). The T3-binding affinity of each mutant receptor was determined using a filter binding assay. In vitro translated receptor (2-4 μl) was incubated for 1 h at 30°C in 500 μl binding buffer (20 mM Tris-HCl, 50 mM KCl, 1 mM MgCl 2 , 1 mM dithiothreitol, pH 8.0) containing 0.01 nM 125 I-T3 (specific activity 3000 μCi /μg) and unlabelled competitor ligand. Bound ligand was separated from free by filtering through Millipore HAWP02500 filters. Scatchard analysis was performed to generate affinity constants (K a ) and the results shown are the mean of three or more separate determinations. Where ligand binding was not detected, the mutants are denoted as 'BND'.
Cell culture and transfection assays JEG-3 cells were grown in Optimem supplemented with 2% (v/v) fetal calf serum (FCS) and 1% (v/v) PSF (Gibco-BRL, Paisley, UK). Eighteen hours prior to transfection the medium was replaced with Optimem containing 2% resin-stripped FCS. Cells were transfected by a 4 h exposure to calcium phosphate with 2 μg (MAL-tk, PAL-tk) or 4 μg (F2-tk) of reporter plasmid, together with 100 ng of wild-type or mutant receptor expression vector and 200 ng of BOS-βgal. Following a 36 h incubation, cells were lysed in buffer containing 25 mM glycine-glycine, 15 mM MgSO 4 , 4 mM NaEGTA, 1 mM DTT and 1% (v/v) Triton X-100, pH 7.8. Luciferase activity was measured using an Autolumat LB 953 luminometer (Berthold, Stevenage, UK). β-galactosidase activity was also determined and used to normalize luciferase values for transfection efficiency.
EBNA cells (293) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and 1% (v/v) PSF (Gibco-BRL). Eighteen hours prior to transfection the medium was replaced with DMEM and 10% FCS depleted of thyroid hormones. Cells were transfected with 500 ng of UASTKLUC, 50 ng of wild-type or 4768 mutant Gal4-TR fusion expression vector and 100 ng of BOS-βgal by a 4-h exposure to calcium phosphate and assayed for luciferase and β-galactosidase activity as described above.
Gel mobility shift assays
The nucleotide sequences of the 32 P-labelled oligonucleotide duplexes used in gel mobility shift assays and the methodology were essentially as described previously . 35 S-labelled mutant proteins were synthesized using a non-coupled transcription and translation system, according to the manufacturer's recommended protocol (Promega, Southampton, UK). Equal volumes of translation product were subjected to SDS-PAGE and the major bands quantified using an Instant Imager (Packard). Equal counts of each mutant receptor (2-4 μl) were pre-incubated on ice for 20 min in buffer (20 mM HEPES, 50 mM KCl, 10% glycerol, 2 mM dithiothreitol, pH 7.8) in the presence of 1 μg poly(dI-dC). In vitro translated hRXRα and triiodo-L-thyronine (T3) were also present where specified. The total amount of reticulocyte lysate in each assay was standardized by the addition of non-programmed translation mixture. 32 P-labelled oligonucleotides were added followed by a further 15-min incubation in a total volume of 20 μl. In addition, where specified, bacterially expressed and purified GST fusions containing the receptor-interactive domains of SRC-1 [GST-SRC'; residues 570-780; 2.4 μg/lane (Heery et al., 1997) ] or ACTR [GST-ACTR'; residues 621-821; 0.6 μg/lane (Chen et al., 1997) ] were added. The protein-DNA complexes were then analysed using polyacrylamide gel electrophoresis (5% T, 3.3% C) in 0.5ϫ TBE (44 mM Tris, 44 mM boric acid, 1 mM EDTA). The assays were replicated using mutant proteins from at least two independent translation reactions.
Protein interaction assays
For the interaction of mutant receptors with the corepressor, a fusion protein (GST-C-SMRT) containing essentially the C-terminus of SMRT (Chen and Evans, 1995) was expressed bacterially, purified and incubated with radiolabelled wild-type or mutant receptors synthesized in vitro as described above. Aliquots of the immobilized fusion protein were incubated with the receptors in HEMG buffer (Yoh et al., 1997) in the presence or absence of 1 μM T3 for 2 h at 4°C then washed three times with NETN buffer (Collingwood et al., 1997) and analysed by SDS-PAGE. Gels were Coomassie stained to check for equal loading of fusion protein, then exposed to autoradiography.
